HOLLYWOOD, Fla.--(BUSINESS WIRE)--Mar 11, 2010 - Despite statistics stating that colorectal cancer is the fourth most frequently diagnosed cancer in men and women in the United States, mortality from colon cancer has decreased slightly over the past 30 years, possibly because of earlier diagnoses through screening and better treatment modalities. Recommendations relating to the latest treatment options were recently highlighted by Paul F. Engstrom, MD, of Fox Chase Cancer Center and chair of the NCCN Guidelines Panel for Colon and Rectal Cancer at the NCCN 15th Annual Conference on March 11, 2010.
NEEDHAM, Mass.--(BUSINESS WIRE)--Mar 11, 2010 - Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that Anthony S. Marucci, President and Chief Executive Officer of Celldex, will present on Tuesday, March 16th, at 8:30 a.m. PDT at the 22nd Annual Roth Capital OC Growth Stock Conference taking place at The Ritz-Carlton, Laguna Niguel in Dana Point, CA.
ROCKVILLE, Md. & LUND, Sweden--(BUSINESS WIRE)--Mar 11, 2010 - Human Genome Sciences, Inc. (Nasdaq: HGSI) and BioInvent International AB (OMXS: BINV) today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies that specifically target antigens discovered by HGS.
IRVINE, Calif.--(BUSINESS WIRE)--Mar 11, 2010 - Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI), a commercial-stage biotechnology company with a focus in oncology, announced today that an overview of the Company's business strategy will be given at the 22nd Annual ROTH Capital Markets Conference on Monday, March 15, 2010, at 8:00 am Pacific Time. The conference is being held at the Ritz-Carlton Hotel in Laguna Niguel, California.
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Mar 11, 2010 - Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the quarter ended January 31, 2010.
PETALUMA, Calif.--(BUSINESS WIRE)--Mar 11, 2010 - Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) today announced that Hoji Alimi, the company's CEO and founder, will present a corporate overview and business update at the Roth Capital Partners 22nd Annual OC Growth Stock Conference to be held at the Ritz Carlton in Laguna Niguel, California.
LOS ANGELES--(BUSINESS WIRE)--Mar 11, 2010 - Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated biotechnology company, today reported financial results for the fourth quarter and full year ended December 31, 2009.
LEXINGTON, Mass.--(BUSINESS WIRE)--Mar 11, 2010 - Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter and full-year 2009 financial results, provided an update on recent progress with its programs, and announced 2010 objectives.
EWING, N.J.--(BUSINESS WIRE)--Mar 11, 2010 - Antares Pharma, Inc. (NYSE Amex: AIS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the 22nd Annual Roth OC Growth Stock Conference on Wednesday, March 17, 2010 at 12:30 p.m. ET (Eastern Time).
WAYNE, Pa.--(BUSINESS WIRE)--Mar 11, 2010 - Safeguard Scientifics, Inc. (NYSE: SFE), a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company's 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.
VANCOUVER — Allon Therapeutics Inc. (TSX: NPC) announced today that a Phase 1 clinical trial of its lead neuroprotective drug, davunetide, which began patient enrolment January 28, 2010, has been completed. The results demonstrated that the intranasal dose range can be broadened and provided additional information on the pharmacokinetic profile of davunetide.
TUSTIN, Calif., March 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) , a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and serious viral infections, today announced financial results for the third quarter of fiscal year (FY) 2010 ended January 31, 2010. The company also provided an update on its clinical programs and corporate developments.
CHICAGO, March 11 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC:ADLS) (BULLETIN BOARD: ADLS) , a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2009.
SOUTH SAN FRANCISCO, Calif., March 11 /PRNewswire/ -- Portola Pharmaceuticals, Inc. today announced that Charles Homcy, M.D., president and chief executive officer, will retire from his current position and assume the role of co-chairman of the board of directors, effective May 1, 2010.
DALLAS, March 11 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC:ACCP) (BULLETIN BOARD: ACCP) announced that it has received reports of significant bioavailability of orally delivered insulin in two independently-conducted animal studies. The studies, which confirm earlier findings, were performed as part of on-going work with commercial collaborators that are evaluating Access' Cobalamin(TM) Oral Drug Delivery Technology.
RIDGEFIELD, Conn., March 11 /PRNewswire/ -- Results from a new online survey of more than 300 practicing endocrinologists and family medicine physicians show that a large majority of physicians (83 percent) indicated that using a team of specialists early in the course of type 2 diabetes (T2D) treatment can help prevent serious T2D-related complications. However, more than nine out of 10 physicians (93 percent)surveyed do not believe their peers are using this team approach.
NEW YORK, March 11 /PRNewswire/ -- Kantar Health, a leading healthcare-focused global consultancy and marketing insights company, today announced that Chief Executive Officer Lynnette Cooke will participate in a panel discussion at the Pharmaceutical Marketing Research Group's (PMRG) 2010 Annual National Conference. The conference will take place March 21-23, 2010, at Disney's Contemporary Resort in Orlando, Florida.
WAYNE, N.J., March 11 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals announced today that an orphan drug designation has been granted by the U.S. Food and Drug Administration (FDA) for ciprofloxacin dry powder inhaler (DPI) for management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis (CF) patients. A similar designation has already been granted by the European Medicines Agency.
|
